All In Biotech

Drug Trial Radar · NCT06786286

A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects

A Phase 1, Open-label Study to Assess the Mass Balance, Metabolism, Excretion and Pharmacokinetics of a Single Subcutaneous Dose of [14C]-ITI-1284 in Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Jan 28, 2025

Primary completion

Mar 26, 2025

Study completion Mar 26, 2025

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Jan 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 30 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

ITI-1284-012 is an open-label, single-dose study to assess the mass balance recovery of radioactivity, and to evaluate the pharmacokinetics, safety and tolerability of ITI-1284 after a single subcutaneous dose of \[14C\]-ITI-1284 in healthy male subjects.

Conditions

  • Healthy Volunteers

Interventions

  • [14C]-ITI-1284Drug

    \[14C\]-ITI-1284 20 mg oral solution (not more than 22 μCi), subcutaneous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mass balance recovery of total radioactivity in urine and feces combinedTime frame: Day 1 up to Day 29
  2. Pharmacokinetics: AUC0-t for total radioactivityTime frame: Day 1 up to Day 29
  3. Pharmacokinetics: AUC0-t for ITI-1284Time frame: Day 1 to Day 8
  4. Pharmacokinetics: Cmax for total radioactivityTime frame: Day 1 up to Day 29
  5. Pharmacokinetics: Cmax for ITI-1284Time frame: Day 1 to Day 8
  6. Pharmacokinetics: Tmax for total radioactivityTime frame: Day 1 up to Day 29
  7. Pharmacokinetics: Tmax for ITI-1284Time frame: Day 1 to Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Site 1

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.